| 任 程,李 洁,冉方兰,卢安静,王 钢.苏黄止咳胶囊联合舒利迭对咳嗽变异性哮喘患者肺功能、免疫功能及诱导痰炎性介质的影响[J].,2020,(17):3363-3366 |
| 苏黄止咳胶囊联合舒利迭对咳嗽变异性哮喘患者肺功能、免疫功能及诱导痰炎性介质的影响 |
| The Effect of Suhuang Zhike Capsule Combined with Seretide on Pulmonary Function, Immune Function and Induced Sputum Inflammatory Mediators in Patients with Cough Variant Asthma |
| 投稿时间：2020-03-07 修订日期：2020-03-31 |
| DOI：10.13241/j.cnki.pmb.2020.17.037 |
| 中文关键词: 舒利迭 咳嗽变异性哮喘 苏黄止咳胶囊 肺功能 免疫功能 诱导痰炎性介质 |
| 英文关键词: Seretide Cough variant asthma Suhuang Zhike capsule Lung function Immune function Induced sputum inflammatory mediators |
| 基金项目:国家中医药管理局基金项目（ZYJC20150419）；重庆市卫生和计划生育委员会医学科研计划项目（20163204） |
|
| 摘要点击次数: 887 |
| 全文下载次数: 506 |
| 中文摘要: |
| 摘要 目的：探讨苏黄止咳胶囊联合舒利迭对咳嗽变异性哮喘（CVA）患者肺功能、免疫功能及诱导痰炎性介质的影响。方法：选取2017年1月-2019年12月期间我院收治的93例CVA患者，按照随机数字表法分为对照组（n=46）和研究组（n=47），对照组患者给予舒利迭治疗，研究组在对照组的基础上联合苏黄止咳胶囊治疗，比较两组患者疗效、肺功能、免疫功能、诱导痰炎性介质以及不良反应情况。结果：研究组治疗2个疗程后的临床总有效率高于对照组（P<0.05）。两组患者治疗2个疗程后第1秒用力呼气容积（FEV1）、用力肺活量（FVC）以及呼气峰值流量（PEF）、CD4+、CD4+/ CD8+均较治疗前升高，且研究组高于对照组（P<0.05）。两组患者治疗2个疗程后CD8+以及诱导痰白介素-6（IL-6）、白介素-8（IL-8）、肿瘤坏死因子-α（TNF-α）水平均较治疗前降低，且研究组低于对照组（P<0.05）。两组不良反应发生率比较无差异（P>0.05）。结论：舒利迭联合苏黄止咳胶囊治疗CVA患者，可有效改善患者肺功能、免疫功能，降低诱导痰炎性介质水平，且不增加不良反应发生率，安全可靠，疗效显著。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of Suhuang Zhike capsule combined with Seretide on pulmonary function, immune function and induced sputum inflammatory mediators in patients with cough variant asthma (CVA). Methods: 93 patients with CVA who were admitted to our hospital from January 2017 to December 2019 were selected, they were randomly divided into control group (n=46) and study group (n=47) by random number table method. Patients in the control group were treated with Seretide, while those in the study group were treated with Suhuang Zhike capsule on the basis of the control group. The therapeutic effect, lung function, immune function, induced sputum inflammatory mediators and adverse reactions were compared between the two groups. Results: The total clinical effective rate of the study group at 2 courses after treatment was higher than that of the control group (P<0.05). The forced expiratory volume in the first second (FEV1), vital capacity (FVC), peak expiratory flow (PEF), CD4+, CD4+/ CD8+ of the two groups at 2 courses after treatment were higher than those before treatment, and those of the study group were higher than those of the control group (P<0.05). The levels of CD8+, interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor -α (TNF -α) in induced sputum of the two groups were lower than those before treatment, and those of the study group were lower than those of the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Suhuang Zhike capsule combined with Seretide is effective in the treatment of patients with CVA. It can effectively improve the lung function and immune function, reduce the level of induced sputum inflammatory mediators, and do not increase the incidence of adverse reactions. It is safe and reliable. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
